Latest Commercialization News

HITIQ Limited has successfully raised $925,000 through an oversubscribed placement, issuing shares at a discount and attaching listed options to support its concussion management technology's commercialisation.

BrainChip Holdings has closed its Share Purchase Plan with subscriptions exceeding the $2 million target by nearly $1 million, complementing a recent $35 million placement. The Board’s decision to accept all applications reflects robust shareholder confidence.

Pacgold has finalized its acquisition of the White Dam Gold Operation in South Australia, setting the stage for a near-term production restart with modest capital investment. The move complements its Queensland projects and offers a clear path to cash flow.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

Lotus Resources reports promising progress at its Kayelekera uranium mine, targeting steady state production by Q1 2026 despite recent sulphuric acid supply constraints. The company is addressing supply issues with new sourcing and an on-schedule acid plant rebuild.

New Murchison Gold Limited reports robust November production at Crown Prince Gold Mine, with ore sales exceeding expectations and a $41.6 million payment received from Westgold Resources.

AdAlta Limited has received a $0.78 million Research and Development Tax Incentive refund for FY2025, using part of it to repay a Radium Capital loan and strengthening its cash position as it nears a key licensing milestone.

Aguia Resources is advancing steadily towards mining commencement at its Três Estradas phosphate project in Brazil, with key infrastructure completed and sales agreements signed for its PAMPAFOS™ fertilizer product.

West Coast Silver and Artemis Resources have signed a non-binding MOU to assess processing Elizabeth Hill silver ore at Artemis’s Radio Hill plant, aiming to fast-track development while managing capital costs.

Ariana Resources has successfully completed its first gold-silver doré pour at the Tavşan Mine in Türkiye, signaling the start of heap-leach production and a ramp-up toward steady-state output by mid-2026.

Argenica Therapeutics has demonstrated that its lead drug candidate ARG-007 does not interfere with the clot-busting agent tenecteplase, fulfilling a critical FDA requirement and advancing its stroke therapy development.

Mach7 Technologies has inked a five-year subscription agreement with UnityPoint Health, marking the first commercial deployment of its new Flamingo Architecture and setting the stage for significant recurring revenue growth.